Anticoagulation for Obese Female in 40s with New AFib and CVD

Risk Stratification

• The European Society of Cardiology recommends anticoagulation for patients with a CHA₂DS₂-VASc score of ≥1, and a score of ≥2 has a Class I recommendation for oral anticoagulation to prevent ischemic stroke and thromboembolism 1
• A CHA₂DS₂-VASc score of 2 or more mandates anticoagulation according to all major guidelines, including the American Heart Association and the European Society of Cardiology 1, 2, 3

Why Anticoagulation is Essential

• Patients with cardiovascular disease and AFib have an annual stroke risk exceeding 2.5% per year, and oral anticoagulation reduces stroke risk by 60-65% compared to no treatment 4
• Approximately 15% of all strokes in the U.S. are attributable to atrial fibrillation, and AFib increases stroke risk approximately fivefold in nonvalvular cases 5

Obesity Considerations

• Obesity is NOT a contraindication to anticoagulation, and weight was not an exclusion criterion in any of the major NOAC trials, according to the European Society of Cardiology 6
• Obese patients (BMI ≥30-35 kg/m²) actually showed trends toward better outcomes in ARISTOTLE and ROCKET-AF trials, as reported by the European Heart Journal 6

Anticoagulant Selection

• Direct oral anticoagulants (DOACs) are preferred over warfarin as first-line therapy, and apixaban, rivaroxaban, edoxaban, or dabigatran are all appropriate choices, according to the European Society of Cardiology and the American College of Cardiology 1, 3, 7
• DOACs have demonstrated superior or non-inferior efficacy to warfarin with reduced intracranial hemorrhage risk, as reported by the European Heart Journal 7

Critical Clinical Pitfalls to Avoid

• The European Society of Cardiology explicitly states that adding antiplatelet treatment to anticoagulation is not recommended for stroke prevention in AFib (Class III, Level B) 1
• Aspirin alone is inferior to oral anticoagulation with comparable bleeding risk, according to the American College of Cardiology and the European Society of Cardiology 1, 3

Bleeding Risk Assessment

• A high bleeding risk (HAS-BLED ≥3) does NOT contraindicate anticoagulation, but prompts more careful monitoring and modification of reversible bleeding risk factors, according to the European Society of Cardiology and the American College of Cardiology 1, 3, 4
• The stroke prevention benefit exceeds bleeding risk in the vast majority of cases, as reported by the European Heart Journal and the American College of Cardiology 4

Monitoring and Follow-up

• After initiating anticoagulation, reassess thromboembolic and bleeding risk periodically, and ensure blood pressure control to reduce both stroke and bleeding risk, according to the European Society of Cardiology and the American College of Cardiology 1, 3, 4
• Avoid concomitant NSAIDs or aspirin unless compelling indication exists, as recommended by the American College of Cardiology and the European Society of Cardiology 4, 8